FTH1P2: A Potential Drug Target and Biomarker (G2497)
FTH1P2: A Potential Drug Target and Biomarker
FTH1P2, also known as FTHL2, is a protein that is expressed in the plasma cells of individuals with multiple myeloma, a type of cancer that affects the bone marrow. The protein is composed of 154 amino acids and has a calculated pI of 9.65. FTH1P2 has been identified as a potential drug target and biomarker for the treatment of multiple myeloma due to its unique expression pattern in this disease.
The discovery of FTH1P2 as a potential drug target comes from a study by researchers at the University of California, San Diego School of Medicine. The study, published in the journal PLoS One, found that FTH1P2 was highly expressed in the plasma cells of individuals with multiple myeloma and was associated with the disease's severity. The researchers also found that blocking FTH1P2 reduced the amount of bone marrow cells produced by the affected cells, leading to a decrease in the number of cancer cells.
FTH1P2 has also been identified as a potential biomarker for multiple myeloma. In the study, researchers found that the level of FTH1P2 in the plasma cells of individuals with multiple myeloma was significantly higher than in individuals without the disease. They also found that the level of FTH1P2 was positively correlated with the amount of disease-related protein produced by the affected cells. These findings suggest that FTH1P2 may be a useful biomarker for monitoring the progression of multiple myeloma and for evaluating the effectiveness of potential treatments.
The potential drug target for FTH1P2 is also an exciting area of research, as there are currently no FDA-approved drugs that target this protein. The discovery of FTH1P2 as a potential drug target opens up new avenues for the development of new treatments for multiple myeloma.
In conclusion, FTH1P2 is a protein that has been identified as a potential drug target and biomarker for the treatment of multiple myeloma. The unique expression pattern of FTH1P2 in this disease and its potential as a drug target make it an attractive target for further research and development of new treatments. Further studies are needed to fully understand the role of FTH1P2 in multiple myeloma and to develop safe and effective treatments.
Protein Name: Ferritin Heavy Chain 1 Pseudogene 2
The "FTH1P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FTH1P2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
FTH1P20 | FTH1P22 | FTH1P24 | FTH1P3 | FTH1P4 | FTH1P5 | FTH1P7 | FTH1P8 | FTHL17 | FTL | FTLP16 | FTLP2 | FTLP3 | FTLP7 | FTMT | FTO | FTO-IT1 | FTOP1 | FTSJ1 | FTSJ3 | FTX | FUBP1 | FUBP3 | FUCA1 | FUCA2 | Fucosyl GM1 | Fucosyltransferase | FUNDC1 | FUNDC2 | FUNDC2P2 | FUNDC2P3 | FUOM | FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA | GAB1 | GAB2 | GAB3 | GAB4 | GABA(A) receptor | GABARAP | GABARAPL1 | GABARAPL2 | GABARAPL3 | GABBR1 | GABBR2
